• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role

    11/8/23 9:50:00 AM ET
    $BMY
    $ILMN
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $BMY alert in real time by email

    New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal of precision medicine.

    According to Straits Research, "North America is dominating the market with the highest revenue and is expected to reach USD 97.32 billion in 2030, growing at a CAGR of 9.7% during the forecast period,"

    Download Free Sample Report PDF @ https://straitsresearch.com/report/precision-medicine-market/request-sample

    Key Drivers

    DNA sequencing technology has undergone significant technological advancements, which have paved the way for a deeper understanding of some diseases like cancer. Depending on the genetic profiles of those individuals, the advancements have made it possible to develop treatments that are better suited to them. Patients with breast, lung, or colorectal cancer who have undergone genetic testing as part of routine patient care can measure this molecular transformation of medicine. As a result, the process's accuracy and the time required to finish it have increased. With the collection of more medical data, there has been an increase in understanding of how the treatment a patient receives affects the patient's overall health. It is possible to use precision medicine for preventive care when interventions target disease risk factors to lower the disease risk. One example of this would be the treatment of high blood pressure to prevent patients from experiencing heart attacks or strokes.

    Growth Opportunities

    Most precision medicine providers focus on developed markets, leaving emerging markets untapped. Large populations at risk for diseases requiring gene sequencing in China, India, Australia, the Middle East, and Africa present an opportunity to expand the precision medicine market. Genetics and precision medicine have made significant progress in developing countries over the past decade regarding regulations, product approvals, and implementation of novel methods and procedures in healthcare.

    Searching for mendelian germline genetic mutations, such as those in cancer genetics, is likely the first step for emerging nations' public healthcare systems. Private healthcare investment funds help small innovative players develop new genetic tests in emerging regions. Developing nations' proper and uncomplicated approval of GINA helped ban genetic discrimination in health insurance and employment. This creates a modern and humanized genomic medicine environment in the country.

    Regional Analysis

    The North American segment dominates the market with the highest revenue, and The United States dominates North America's precision medicine market. Advanced research and development in molecular diagnostics and targeted therapeutics have significantly aided our understanding of the biology of various infectious diseases and forms of cancer, such as lung cancer, breast cancer, and colorectal cancer.

    Several well-established diagnostics manufacturers in North America are focusing on expanding their portfolios of NGS-based molecular diagnostics and collaborating with service providers and pharmaceutical behemoths to co-market molecular diagnostics solutions alongside their complementary precision medicine solutions. In addition, the U.S. government finances new molecular diagnostics and precision medicine start-ups.

    Key Highlights

    • The global precision medicine market size is projected to reach USD 280.67 billion by 2030, growing at a CAGR of 11.12% during the forecast period (2022–2030).
    • Based on the ecosystem, the global precision medicine market is segmented into sciences, precision diagnostics, precision therapeutics, and digital health and information technology. The precision therapeutics segment is dominating the market and is expected to grow at a CAGR of 11.62% during the forecast period.
    • Based on application, the global precision medicine market is segmented into oncology, neurology/psychiatry, infectious diseases, gastroenterology, cardiovascular, endocrinology, rheumatology, etc. The oncology segment is the most dominant and is expected to grow at a CAGR of 11.21% during the forecast period.

    Competitive Analysis

    The global precision medicine market's major key players are Bristol-Myers Squibb Company, Illumina, Inc., Pacific Biosciences of California, Inc., AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Premaitha Health plc, QIAGEN N.V., Johnson and Johnson, and Asuragen, Inc.

    Market News

    • May 2022- Illumina Introduced New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy. The first companion diagnostic claim for Illumina's TruSightTM Oncology Comprehensive (EU) test enables targeted therapy for patients with NTRK fusion cancer using Bayer's VITRAKVI® (larotrectinib).
    • May 2022- Illumina and Allegheny Health Network Assessed In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care. Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving Western Pennsylvania, have partnered to evaluate the impact of in-house comprehensive genomic profiling (CGP) on patient care.
    • June 2022- Bristol Myers Squibb Acquired Turning Point Therapeutics, a Leading Precision Oncology Company. Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) have announced a definitive merger agreement.

    Global Precision Medicine Market: Segmentation

    By Ecosystem

    • Applied Sciences
    • Precision Diagnostics
    • Precision Therapeutics
    • Digital Health and Information Technology

    By Application

    • Oncology
    • Neurology/psychiatry
    • Infectious diseases
    • Gastroenterology
    • Cardiovascular
    • Endocrinology
    • Rheumatology

    By Regions

    • North America
    • Europe
    • Asia-Pacific
    • Rest-of-the-World (ROW)

    Get Detailed Market Segmentation @ https://straitsresearch.com/report/precision-medicine-market/segmentation

    About Straits Research Pvt Ltd.

    Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, specially designed and presented for decision making and ROI.

    Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

    For more information on your target market, please contact us below:

    Phone: +1 646 480 7505 (the U.S.)

    +91 8087085354 (APAC)

    +44 208 068 9665 (the U.K.)

    Email: [email protected]

    Follow Us: LinkedIn | Facebook | Instagram | Twitter



    Primary Logo

    Get the next $BMY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BMY
    $ILMN
    $TPTX

    CompanyDatePrice TargetRatingAnalyst
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    Illumina Inc.
    $ILMN
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    Illumina Inc.
    $ILMN
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    More analyst ratings

    $BMY
    $ILMN
    $TPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

      SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's

      7/10/25 4:05:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

      Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access Only about 2 in 10 eligible patients currently receive cell therapy treatment; today's announcement will reduce unnecessary barriers for patients and providers Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma® (idecabtagene vi

      6/26/25 10:05:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $ILMN
    $TPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:20:13 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:18:28 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $ILMN
    $TPTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $ILMN
    $TPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      12/6/24 10:11:24 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Illumina Inc.

      SC 13G - ILLUMINA, INC. (0001110803) (Subject)

      12/5/24 7:27:01 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      11/12/24 3:59:44 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $BMY
    $ILMN
    $TPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Illumina downgraded by Scotiabank with a new price target

      Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

      7/11/25 8:11:04 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $ILMN
    $TPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Commercial Officer Cunningham Everett covered exercise/tax liability with 4,248 shares, decreasing direct ownership by 9% to 41,942 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      7/8/25 5:59:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by EVP, Chief Strategy Officer Shibutani Hiroshi Chris

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      7/2/25 5:07:18 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ullem Scott B. was granted 307 shares, increasing direct ownership by 4% to 8,137 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      7/2/25 4:26:43 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $BMY
    $ILMN
    $TPTX
    SEC Filings

    See more
    • SEC Form 8-K filed by Illumina Inc.

      8-K - ILLUMINA, INC. (0001110803) (Filer)

      6/23/25 9:24:49 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:25:42 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:57 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $ILMN
    $TPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

      Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

      3/25/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BMY
    $ILMN
    $TPTX
    Financials

    Live finance-specific insights

    See more
    • Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

      SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's

      7/10/25 4:05:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

      Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI

      6/18/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, de

      6/17/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care